🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07647692
Starting soon Observational

Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT

NCT07647692 · tracked via the Priya Life Science China tracker
Sponsor
Peking University People's Hospital
Phase
Observational
Started
2026-06-01
Last updated
2026-06-15

Condition(s) studied

Pulmonary NodulesLung NeoplasmsAdenocarcinoma of Lung

Investigational drug(s) / intervention(s)

Serial Thin-Slice Chest CT

Serial Thin-Slice Chest CT: Routine-care thin-slice non-contrast chest CT (slice thickness ≤ 1.5 mm, lung-window reconstruction) acquired at baseline and at subsequent clinical follow-up timepoints (minimum inter-scan interval \> 1 month). Images are resampled to 1 × 1 × 1 mm and intensity-normalized before analysis. No additional imaging, radiation exposure, or procedures are performed for this study; all imaging is part of routine clinical care.

Study summary

Pulmonary ground-glass nodules (GGNs) are commonly found on chest CT scans. Some stay stable for years, while others slowly or rapidly turn into lung cancer. Doctors currently follow these nodules with repeated CT scans, but it is difficult to tell ahead of time which nodules will progress, how fast they will progress, and which ones can be safely monitored rather than immediately treated.

This observational study aims to develop and validate an artificial intelligence (AI) model that uses each patient's series of CT scans over time to predict the long-term growth behavior of a GGN. The research team will collect three retrospective single-center cohorts from Peking University People's Hospital (a development cohort and two internal test cohorts, one from surgically resected patients and one from non-operated patients followed by serial CT) as well as a prospective multi-center validation cohort enrolled after the AI model is locked.

For every patient, each GGN is automatically segmented in three dimensions on every CT scan. A deep learning model extracts imaging features at each timepoint and feeds the sequence of features, together with the actual times between scans, into a time-aware sequence model. The model is trained to predict (i) whether the nodule will show radiological progression at 1, 3, and 5 years after baseline, and (ii) which of four long-term growth patterns the nodule will follow: stable, slow progression, slow-then-rapid progression, or rapid progression. In patients who were ultimately resected, the histopathological diagnosis serves as a secondary reference standard.

This is an observational study. No experimental treatment is given. All CT scans and clinical visits are part of routine clinical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years. * Persistent pulmonary ground-glass nodule (pGGN or mGGN, 5-30 mm) on thin-slice chest CT (slice thickness ≤ 1.5 mm). * Baseline and follow-up thin-slice chest CTs of sufficient quality for 3D segmentation and registration. * Minimum interval between any two consecutive CTs \> 1 month. * Complete baseline clinical data available (age, sex, smoking history, family history of malignancy, relevant comorbidities). Cohort-specific inclusion * Group 1 (Development): surgical resection of the target GGN at PKUPH between Jan 2007 - Jun 2025, with ≥ 2 pre-operative thin-slice CTs available. * Group 2 (Surgical internal test): surgical resection at PKUPH between Jul 2025 - Jan 2026, with ≥ 2 pre-operative thin-slice CTs available. * Group 3 (Non-surgical internal test): non-operative management at PKUPH between Jan 2020 - Dec 2025, with ≥ 3 thin-slice CTs of the target GGN available. * Group 4 (Prospective external validation): prospective enrollment after model lock at participating centers, baseline CT plus ≥ 2 planned routine follow-up thin-slice CTs. Exclusion Criteria: * Coexisting severe pulmonary disease that obscures evaluation of the target GGN (e.g., active pulmonary tuberculosis, severe interstitial lung disease). * Prior history of any other thoracic malignancy, or active extrathoracic malignancy under treatment within 5 years, that would confound interpretation of the target GGN. * CT image quality insufficient for registration and feature extraction (severe motion artifact, slice thickness \> 1.5 mm at any required timepoint, or extensive metallic artifact projecting over the target GGN). * Pure solid nodule with no ground-glass component. * Target GGN already received treatment (resection, ablation, or radiotherapy) prior to the baseline CT used in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University People's Hospital Beijing Beijing Municipality

More Peking University People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07647692 on ClinicalTrials.gov ↗ ← All trials in China